R&D channel feed

J&J and Gen­mab tout first-line in­jectable Darza­lex for mul­ti­ple myelo­ma: #ASH23

Last year

FDA sets late 2024 de­ci­sion dead­line for Pfiz­er’s 'pan-he­mo­phil­i­a' drug: #ASH23

Last year
FDA+

Bris­tol My­ers bags Sys­tIm­mune’s lung can­cer drug for $800M up­front in its third ADC-fo­cused pact of 2023

Last year
Deals

Biotech CAR-T roundup: Au­to­lus, Gra­cell tout ear­ly-stage da­ta at #ASH23

Last year
Cell/Gene Tx

Bris­tol My­ers and 2sev­en­ty bio's Abec­ma sur­vival da­ta raise ques­tions ahead of FDA’s ad­vi­so­ry com­mit­tee meet­ing: #ASH23

Last year

Bi­par­ti­san House bill seeks to boost pe­di­atric drug de­vel­op­ment via new FDA penal­ties for non­com­pli­ance

Last year
Pharma
FDA+

Af­ter two his­toric ap­provals, Ed­i­tas un­veils promis­ing ear­ly re­sults for its sick­le cell ther­a­py: #ASH23

Last year

Ex­clu­sive: Aviv Regev talks three years of lead­ing Genen­tech’s re­search, the fu­ture of AI, and not mak­ing No­bel pre­dic­tions

Last year
People
AI

Au­toim­mune pa­tients in CAR-T study see strik­ing im­prove­ments across lu­pus and oth­er dis­eases

Last year
Cell/Gene Tx

Roche part­ner touts ear­ly al­lo­gene­ic CAR-T da­ta at #ASH23, but dura­bil­i­ty re­mains key ques­tion

Last year
Cell/Gene Tx

Ar­cel­lx, Kite aim to keep chip­ping away at Carvyk­ti ad­van­tage with new mul­ti­ple myelo­ma da­ta: #ASH23

Last year
Cell/Gene Tx

Cor­rect­ed: BeiGene builds out long-term case for Brukin­sa in CLL with three-year fol­low-up da­ta

Last year
Pharma

Roche touts full da­ta for drug in first-line PIK3CA-mu­tat­ed breast can­cer

Last year

Gavi an­nounces $1.8B for vac­cine ac­cess, pan­dem­ic pre­pared­ness ef­forts in Africa

Last year
Pharma
Manufacturing

How one lab's decades­long search for the 'holy grail' of sick­le cell led to the first CRISPR ther­a­py

Last year
Cell/Gene Tx
In Focus

Af­ter ink­ing re­verse merg­er, Graphite Bio di­vests gene edit­ing pipeline to new­ly-formed biotech

Last year
Startups
Cell/Gene Tx

Sol­id tu­mor biotech’s poly­mer nanopar­ti­cle-drug con­ju­gate clears ear­ly-stage hur­dle, spark­ing PhII plans

Last year

Allen In­sti­tute and Chan Zucker­berg Ini­tia­tive launch re­search cen­ter to probe mys­ter­ies of the cell

Last year

Sanofi CEO Paul Hud­son pitch­es 12 block­busters in a bid to con­vince in­vestors on boost­ing R&D spend

Last year
Pharma

Mer­ck de­tails PhII TIG­IT/PD-1 fail in lung can­cer

Last year

Up­dat­ed: 89bio prices $150M pub­lic of­fer­ing for PhI­II de­vel­op­ment of NASH drug

Last year
Financing

Re­gen­eron heads to­ward FDA fil­ing for mul­ti­ple myelo­ma bis­pe­cif­ic, set­ting up show­down with J&J, Pfiz­er: #ASH23

Last year

Brain cell at­las for Alzheimer's dis­ease is the tar­get of NI­H's new col­lab­o­ra­tion with 10x Ge­nomics

Last year

Wave makes $100M pub­lic of­fer­ing af­ter dos­ing first sub­jects with GSK-part­nered RNA edit­ing drug

Last year
Financing
First page Previous page 60616263646566 Next page Last page
A service from the Financial Times